Compare Altria Group Inc (MO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Altria Group (MO) trades at $73.16, up 2.09% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with 39% net income margin and generates robust operating cash flow of $9.3B. Recent earnings show alternating beats and misses, while analyst consensus remains positive with 61.5% buy ratings despite negative shareholder equity of -$2.24B.

MO offers a high dividend yield but faces structural challenges including declining cigarette volumes and regulatory uncertainty. The stock trades below analyst consensus target of $69.71, suggesting limited upside. Key risks include negative equity, margin compression, and dependence on declining tobacco products despite smoke-free initiatives.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.